XCell ATF® Intensification solves upstream manufacturing capacity, productivity, and throughput challenges.
Designed and engineered as a complete solution, the XCell™ Lab System integrates a modern controller, XCell ATF® Devices, software and flow sensors into a complete solution.
- Engineering-designed controller promotes increased intensification
- Configurable set-up delivers high throughput - a single manifold supports up to 8 XCell ATF® Devices
- Software enables precise technical control with a user-friendly interface
- New XCell ATF® 1 Device is fit for low volume intensification ready for scale-up
- Repligen global technical support ensures successful implementation and scale-up
XCell ATF® Technology helps simplify and intensify upstream processes to deliver more product, faster. Intensified processes achieve higher cell densities, require smaller bioreactors and consume less suite time. Increase throughput, productivity, and capacity in both clinical and commercial manufacturing.
DELIVER MORE, FASTER
Increase throughput
More programs, more molecules
Increase productivity
More product per batch
Increase capacity
More batches per facility
Execute high roi BUSINESS DECISIONS
Reduce bioreactor size up to 10 fold
For example from 10,000 L to 1,000 L
Advance your program
Smaller, flexible intensified processes
Re-think your facility
Lower cost, lower risk, faster results
XCell™ Lab Controller
Design simplicity
Software, hardware, device
Precision pumping
enables robust development
More process data
for improved characterization
Reduced media cost
XCell ATF® Cell retention technology simplifies and fast-tracks upstream intensification development for gene therapy, fed-batch intensification, seed train intensification, perfusion, and media exchange applications.
XCell ATF® Technology by application
XCell ATF® intensification from Process development to manufacturing
The XCell ATF® Intensification simplifies and fast-tracks upstream intensification development from PD to commercial scale. Intensification increases throughput, accelerates tech transfer and optimizes your process in clinical manufacturing and MSAT while increasing bioreactor productivity and reducing costs in commercial manufacturing. Higher productivity, smaller bioreactors and higher throughput with shorter times to harvest, combine to mitigate facility expansion risks and capital costs.
XCell Atf® Technology in Gene Therapy and Adenovirus
The XCell ATF® Solution delivers an efficiency boost both pre- and post-transfection in the gene therapy workflow. Increase yield and save time during host cell expansion and pre-transfection preparation. Post-transfection options exist for multiple host types.
Gene Therapy Manufacturing 2.0
AAV Production
- Boost output
- Save time
Adenovirus and Vaccine Production
- Boost output
- Produce clarified harvest
- Go straight to downstream
Xcell ATF® Delivers 10x VCD and Lowers cogs
Source: ExpreS2ion Technologies
Higher productivity and lower COGs for malaria therapeutic candidate.
- 10X VCD more than 2-week Fed- Batch (350 x 106 cells/mL)
- 50% decrease in bioreactor time
- 20-fold increase in yield
How XCell ATF® Technology works
The XCell ATF® System is based on award-winning alternating tangential flow (ATF) technology, created by the action of a diaphragm moving upward and downward within a pump head, connected to a filter housing and attached to a bioreactor. Alternating tangential flow is attained by the action of a diaphragm pump.
XCell ATF® Devices and controllers
The XCell ATF® System delivers a complete solution for upstream intensification with robust hardware software integration. Available in single-use and stainless steel formats with sizes from lab-scale (2 L) to process scale (5000 L). Each system consists of an XCell ATF® Device, XCell™ Controller, software, tubing and sensors.
Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, to ensure business continuity for our customers.
REPLIGEN technical support ENSUres Success
The Repligen Field Application team with expertise in XCell ATF® technology will provide support from consultation to implementation globally.
Consultation
- Theory
- Technology fit
- Experimental plan
Evaluation
- Demonstration
- Training
- Data analysis
Development
- Optimization
- Flow Path sizing
- System sizing
Implementation
- Scale-up
- Validation
- Long-term training plan
Resources
XCell ATF® Devices and XCell™ Controllers Seismic Anchorage Report
XCell ATF® 1 Device Set-up Guide
XCell™ Lab Controller User Guide
XCell ATF® 2 Single-use Device Start-up Guide
XCell ATF® 6 Single-use Device Start-up Guide
XCell ATF® 10 Single-use Device Start-up Guide
XCell™ C24:V3 Controller User Guide
XCell ATF® System with C410:V4B Controller
High Productivity Harvest: A Novel Approach to Fed-batch Process Intensification
Mitigation of Protein Retention in Perfusion Process and Effect of Filter Pore Size
Demonstration of XCell ATF® 2 and XCell ATF® 6 Single-use Performance
Mitigation of Protein Retention in High Density Perfusion Process
Tools for Intensification of Cell Culture Production and Continuous Downstream Processing
ATF Perfusion Technology: Improved Fed-Batch Throughput and Reduced Seed Train Expansion
Special Report on Continuous Bioprocessing: Upstream, Downstream, Ready for Prime Time?
WuXi Biologics Expands Perfusion Cell Culture Capabilities using ATF 10 System
Continuous Manufacturing: A Changing Processing Paradigm
Developing an upstream process for a monoclonal antibody including medium optimization
Repligen Corporation
MSD Animal Health
July 2022
Frequently asked questions | perfusion